EVKEEZA

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Kidney DiseaseHypercholesterolemiaHypertriglyceridemiaHomozygous Familial HypercholesterolemiaDiabetic Kidney Disease (DKD)

245 competitors in Kidney Disease

#DrugCompanyPhaseTrials

1

EVKEEZA

Regeneron

Phase 3

102

Victoza

Novo Nordisk

Phase 3

13

Evrenzo

Astellas

Phase 3

14

Zemplar

AbbVie

Phase 3

15

Reata

Biogen

Phase 3

16

Invirase

Roche

Phase 3

17

Edarbi

Takeda

Phase 3

18

Myfortic

Novartis

Phase 3

—9

Aranesp

Amgen

Phase 3

—10

Gazyva

Roche

Phase 3

—Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Homozygous Familial Hypercholesterolemia4 trials

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Completed·Regeneron·Phase 3·NCT03409744·116 enrolled

Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

Completed·DDaniel Gaudet·Phase 3·NCT05611528·10 enrolled

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Completed·Regeneron·Phase 3·NCT04233918·20 enrolled

Show 1 more trial

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Completed·Regeneron·Phase 3·NCT03399786·65 enrolled

NAC2 trials

Compassionate Use of Evinacumab

Approved for marketing·Regeneron··NCT06500598

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Completed·Regeneron·Phase 1·NCT03146416·96 enrolled

Hypertriglyceridemia2 trials

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Terminated·Regeneron·Phase 2·NCT04863014·21 enrolled

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Completed·Regeneron·Phase 2·NCT03452228·52 enrolled

Hypercholesterolemia1 trial

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Completed·Regeneron·Phase 2·NCT03175367·272 enrolled

Diabetic Kidney Disease (DKD)1 trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease

Recruiting·Regeneron·Phase 2·NCT07271186·270 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News